HC Wainwright Reaffirms Buy Rating for Xeris Biopharma (NASDAQ:XERS)

HC Wainwright reaffirmed their buy rating on shares of Xeris Biopharma (NASDAQ:XERS) in a report published on Thursday morning, Benzinga reports. The brokerage currently has a $6.00 price objective on the stock. HC Wainwright also issued estimates for Xeris Biopharma’s Q3 2024 earnings at ($0.10) EPS, FY2024 earnings at ($0.42) EPS, FY2025 earnings at ($0.23) EPS, FY2026 earnings at $0.05 EPS, FY2027 earnings at $0.27 EPS and FY2028 earnings at $0.49 EPS.

Separately, Piper Sandler reiterated an overweight rating and issued a $3.00 price objective (down from $4.00) on shares of Xeris Biopharma in a research report on Friday, May 10th.

Xeris Biopharma Trading Up 2.7 %

Shares of XERS opened at $2.69 on Thursday. Xeris Biopharma has a twelve month low of $1.46 and a twelve month high of $3.26. The firm has a market capitalization of $398.81 million, a P/E ratio of -5.72 and a beta of 2.72. The firm’s 50-day moving average is $2.31 and its two-hundred day moving average is $2.28.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $48.07 million for the quarter, compared to analysts’ expectations of $46.80 million. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. During the same quarter in the prior year, the firm posted ($0.14) EPS. Analysts predict that Xeris Biopharma will post -0.4 EPS for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Large investors have recently bought and sold shares of the stock. Simplicity Wealth LLC purchased a new stake in shares of Xeris Biopharma in the second quarter valued at $27,000. Bayesian Capital Management LP acquired a new stake in shares of Xeris Biopharma during the 1st quarter worth about $37,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Xeris Biopharma by 4,512.5% during the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after buying an additional 15,929 shares in the last quarter. Quarry LP acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at approximately $47,000. Finally, Eagle Asset Management Inc. purchased a new position in shares of Xeris Biopharma during the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.